Evidence map›Paper›PMID 34520490›Full record

ArticlePloS one2021

Analysis of amyloid-like secondary structure in the Cryab-R120G knock-in mouse model of hereditary cataracts by two-dimensional infrared spectroscopy.

Ariel M Alperstein, Kathleen S Molnar, Sidney S Dicke, Kieran M Farrell, Leah N Makley, Martin T Zanni, Usha P Andley

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ariel M AlpersteinDepartment of Chemistry, University of Wisconsin, Madison, Wisconsin, United States of America.ORCID 0000-0003-1310-1081
Kathleen S MolnarViewPoint Therapeutics, San Francisco, California, United States of America.
Sidney S DickeDepartment of Chemistry, University of Wisconsin, Madison, Wisconsin, United States of America.ORCID 0000-0002-5925-9207
Kieran M FarrellDepartment of Chemistry, University of Wisconsin, Madison, Wisconsin, United States of America.ORCID 0000-0003-4075-1311
Leah N MakleyViewPoint Therapeutics, San Francisco, California, United States of America.
Martin T ZanniDepartment of Chemistry, University of Wisconsin, Madison, Wisconsin, United States of America.
Usha P AndleyWashington University School of Medicine, Department of Ophthalmology and Visual Sciences St. Louis, St. Louis, Missouri, United States of America.ORCID 0000-0001-7049-7591
University of Wisconsin–Madison · USViewpoints Research Institute · US

Funding

ROLE OF OXYGEN IN OCULAR PATHOLOGYR01EY005681 · NEI · WASHINGTON UNIVERSITY · PI ANDLEY, USHA P · 1985 to 2018
$7.3M
Crystallin aggregation and stabilizationR01GM102387 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI ZANNI, MARTIN T · 2014 to 2017
$1.1M
Examining Amyloid-β Structure During the Progression of Alzheimer’s Disease using an Immuno-2DIR-SensorR21AG061602 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI ZANNI, MARTIN T · 2019 to 2020
$409k
NEI NIH HHS R01 EY005681NIA NIH HHS R21 AG061602NIGMS NIH HHS R01 GM102387
6 · The paper itself

Abstract

αB-crystallin is a small heat shock protein that forms a heterooligomeric complex with αA-crystallin in the ocular lens. It is also widely distributed in tissues throughout the body and has been linked with neurodegenerative diseases such as Alzheimer's, where it is associated with amyloid fibrils. Crystallins can form amorphous aggregates in cataracts as well as more structured amyloid-like fibrils. The arginine 120 to glycine (R120G) mutation in αB-crystallin (Cryab-R120G) results in high molecular weight crystallin protein aggregates and loss of the chaperone activity of the protein in vitro, and it is associated with human hereditary cataracts and myopathy. Characterizing the amorphous (unstructured) versus the highly ordered (amyloid fibril) nature of crystallin aggregates is important in understanding their role in disease and important to developing pharmacological treatments for cataracts. We investigated protein secondary structure in wild-type (WT) and Cryab-R120G knock-in mutant mouse lenses using two-dimensional infrared (2DIR) spectroscopy, which has been used to detect amyloid-like fibrils in human lenses and measure UV radiation-induced changes in porcine lenses. Our goal was to compare the aggregated proteins in this mouse lens model to human lenses and evaluate the protein structural relevance of the Cryab-R120G knock-in mouse model to general age-related cataract disease. In the 2DIR spectra, amide I diagonal peak frequencies were red-shifted to smaller wavenumbers in mutant mouse lenses as compared to WT mouse lenses, consistent with an increase in ordered secondary structure. The cross peak frequency and intensity indicated the presence of amyloid in the mutant mouse lenses. While the diagonal and cross peak changes in location and intensity from the 2DIR spectra indicated significant structural differences between the wild type and mutant mouse lenses, these differences were smaller than those found in human lenses; thus, the Cryab-R120G knock-in mouse lenses contain less amyloid-like secondary structure than human lenses. The results of the 2DIR spectroscopy study confirm the presence of amyloid-like secondary structure in Cryab-R120G knock-in mice with cataracts and support the use of this model to study age-related cataract.

Indexed as

Gene Knock-In TechniquesSpectrophotometry, Infraredalpha-Crystallin B ChainAmyloidAnimalsCataractDisease Models, AnimalFormaldehydeHumansLens, CrystallineMiceMice, Inbred C57BLMutant ProteinsParaffin EmbeddingProtein Structure, SecondaryTissue Fixationalpha-Crystallin B ChainAmyloidFormaldehydeMutant Proteins

Identifiers

PMID34520490
PMCPMC8439473
OpenAlexW3201224237

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.